United Kingdom

People: AtriCure Inc (ATRC.OQ)

ATRC.OQ on NASDAQ Stock Exchange Global Market

16 Aug 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Drake, Scott 

Mr. Scott William Drake serves as Independent Chairman of the Board of AtriCure, Inc. Mr. Drake currently serves as the President and Chief Executive Officer of ViewRay, a publicly-held medical device company with global operations in radiation therapy and imaging technologies. Mr. Drake was most recently the President, Chief Executive Officer, and member of the Board of Directors of The Spectranetics Corporation from 2011 to 2017. Spectranetics, acquired by Royal Philips in August of 2017, was a publicly-held medical device company that developed, manufactured and distributed single-use medical devices used in minimally invasive procedures within the cardiovascular system. Prior to joining Spectranetics, Mr. Drake served as Senior Vice President, Operations, of DaVita, Inc., a leading U.S. provider of kidney care and dialysis. Previously, Mr. Drake spent 17 years in several leadership positions within numerous healthcare business units at Covidien. From 2006 to 2009, he was President of Covidien’s Respiratory and Monitoring Solutions Global Business Unit, a $1.5 billion business with 8,000 employees. Mr. Drake has also served on the Board of Directors for The Zayo Group Holdings, Inc. since November 2018. Mr. Drake is Chairperson of the AdvaMed Radiation Therapy Sector and a board member of the Medical Device Manufacturers Association (MDMA). Mr. Drake earned a B.S. in Business Administration from Miami University of Ohio.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 124,991
Long-Term Incentive Plans, USD --
All Other, USD 91,437
Fiscal Year Total, USD 216,428

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Scott Drake


Michael Carrel


Andrew Wade


Douglas Seith


Justin Noznesky


Salvatore Privitera

As Of  31 Dec 2018